Hepatitis New

Approx. Rs 15,000 / BottleGet Latest Price

The medicinal product “Sofoskast” is treated with a chronic form of Hepatitis C. Complex therapy with the use of this drug and other medications are prescribed for adult patients. The drug also treats patients with HIV and co-infections. The active component of the Sofokast tablets is sofosbuvir. They are coated and contain 400 mg of the basic substance. The package contains 28 tablets.

Indications for use of the drug

The drug “Sofosbuvir 400mg” is prescribed for patients with hepatitis C when the disease has passed into a chronic form. A combined approach is used for the effectiveness of treatment. It is possible to use medicament in cases when the patient has HIV in addition to hepatitis.

Contraindications to taking the drug “Sofosbuvir”

The drug is not used for hypersensitivity to substances that are present in its composition. Despite the fact that the drug does not affect fertility, it is rarely prescribed to women in their reproductive years. The use of the drug during pregnancy and breastfeeding is not recommended, as it can be harmful to the child. When pregnancy occurs, the combination of Sofosbuvir with such drugs as Interferon alfa and Ribavirin may have a negative effect on its course. For this reason, during the period of treatment, the child’s bearing is undesirable. The experiments, during which the drug “buy sofosbuvir online” was tested in animals, showed that this drug has a slightly negative impact on the offspring. Before you start taking it, you should carefully study the instructions for the drug and consult with a specialist.

Side Effect

• Side effects are fully dependent on those drugs that are used in addition to Sofosbuvir, t. the main component can cause an only headache and mild weakness.
• We describe the possible negative effects with different combinations of Sofosbuvir in the course of treatment at 12 weeks:
• Ribavirin, more than 10% of cases. Blood can decrease the concentration of hemoglobin and increase the bilirubin index, insomnia, nausea may occur.
• Ribavirin, up to 10 %. Anemia, depression, dyspnea, cough, disorders in the digestive tract, hair loss, itching on the skin, cramps, pains in the joints and back and some others.
• Interferon alfa and Ribavirin, more than 10% of cases. There is anemia, a decrease in the number of platelets and lymphocytes, impaired appetite, dizziness, insomnia, shortness of breath, diarrhea, vomiting, nausea, increased bilirubin, myalgia, joint pain, irritability, rashes and itching on the skin, fever,
• Interferon alfa and ribavirin, less than 10 %. Depression, anxiety, weight loss, migraine, impaired vision, memory and concentration, constipation, reflux, cramps, back and chest pain, asthenia, hair loss.

Additional Information:

• Delivery Time: 1 To 2 Days

Approx. Rs 17,500 / BottleGet Latest Price

VELAKAST TABLETS

VELAKAST is a fixed-dose combination tablet containing sofosbuvir and velpatasvir for oral administration. Sofosbuvir is a nucleotide analog HCV NS5B polymerase inhibitor and velpatasvir is an NS5A inhibitor. Each tablet contains 400 mg sofosbuvir and 100 mg velpatasvir. The tablets include the following inactive ingredients: copovidone, croscarmellose sodium, magnesium stearate, and microcrystalline cellulose. The tablets are film-coated with a coating material containing the following inactive ingredients: Titanium Dioxide IP and Brilliant Blue FCF, polyethylene glycol, polyvinyl alcohol, talc, and titanium dioxide.

Effect of the drug

Thanks to the powerful composition of the drug, Velakast APRAZER HEALTHCARE is widely used to fight the hepatitis C virus of genotypes 1-6. The drug may be given as a monotherapy or for combined treatment with or without cirrhosis. The high effectiveness of the drug against all genotypes of HCV is due to the presence in its composition:

Sofosbuvir: The IUPAC name for sofosbuvir is (S)-Isopropyl 2-((S)-(((2R,3R,4R,5R)-5(2,4-dioxo-3,4-dihydropyrimidin- 1(2H)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran- 2yl)methoxy  (phenoxy)phosphorylamino)propanoate. It has a molecular formula of C22H29FN3 O9 P and a molecular weight of 529.45. Sofosbuvir is a white to off-white crystalline solid with a solubility of at least 2 mg/mL across the pH range of 2–7.7 at 37°C and is slightly soluble in water.

Velpatasvir: The IUPAC name for velpatasvir is Methyl {(1R)-2-[(2S,4S)-2-(5-{2[(2S,5S)-1-{(2S)-2-[(methoxycarbonyl) amino]-3-methylbutanoyl}-5-methylpyrrolidin-2-yl]1,11-dihydro[2]benzopyrano[4′,3′:6,7]naphtho[1,2-d]imidazol-9- yl}-1H-imidazol-2-yl)-4(methoxymethyl)pyrrolidin-1-yl]-2-oxo-1-phenylethyl}carbamate. It has a molecular formula of C49H54 N8 O8 and a molecular weight of 883.0. Velpatasvir is practically insoluble (less than 0.1 mg/mL) above pH 5, slightly soluble (3.6 mg/mL) at pH 2, and soluble (greater than 36 mg/mL) at pH 1.2.

Mechanism of Action

VELAKAST is a fixed-dose combination of sofosbuvir and velpatasvir which are direct-acting antiviral agents against the hepatitis C virus Sofosbuvir is an inhibitor of the HCV NS5B RNA-dependent RNA polymerase, which is required for viral replication. Sofosbuvir is a nucleotide prodrug that undergoes intracellular metabolism to form the pharmacologically active uridine analog triphosphate (GS-461203), which can be incorporated into HCV RNA by the NS5B polymerase and acts as a chain terminator. In a biochemical assay, GS-461203 inhibited the polymerase activity of the recombinant NS5B from HCV genotype 1b, 2a, 3a and 4a with an IC50 value ranging from 0.36 to 3.3 micromolar. GS-461203 is neither an inhibitor of human DNA and RNA polymerases nor an inhibitor of mitochondrial RNA polymerase. Velpatasvir is an inhibitor of the HCV NS5A protein, which is required for viral replication. Resistance selection in cell culture and cross-resistance studies indicates velpatasvir targets NS5A as its mode of action.

OVERDOSAGE

No specific antidote is available for overdose with VELAKAST. If overdose occurs the patient must be monitored for evidence of toxicity. Treatment of overdose with VELAKAST consists of general supportive measures including monitoring of vital signs as well as observation of the clinical status of the patient. Hemodialysis can efficiently remove the predominant circulating metabolite of sofosbuvir, GS-331007, with an extraction ratio of 53%. Hemodialysis is unlikely to result in significant removal of velpatasvir since velpatasvir is highly bound to plasma protein.

HOW SUPPLIED AND STORAGE

Each bottle contains 28 tablets and is closed with a child-resistant closure. Storage: Store below 30°C

Additional Information:

• Delivery Time: 1 To 2 Days

Approx. Rs 2,100 / BottleGet Latest Price

Daclafab 60mg tablets?

Daclafab is an innovative antiviral drug. The active substance Daclatasvir (60 
mg) is an inhibitor of the nonstructural protein 5A (NS5A). The drug is used with an NS5Binhibitor, so Daclafab buy in Moscow is recommended in combination with Sofosbuvir.

Daclafab is a licensed generic drug. It is produced by several 
pharmaceutical companies, including Natco Pharma (India), accordingly the price of Daclatasvir may 
vary.

Description?

Daclafab is an inhibitor of the viral (hepatitis C virus) protein NS5A, which is used in the replication of hepatitis C virus within the liver cells (hepatocytes) and, thus, prevents the virus from entering infected hepatocytes into the blood. Thanks to this action, it is possible to prevent the spread of the virus in the body. 

Daclafab (Daclatasvir) is a highly specific direct action agent against hepatitis C virus (HCV) and does not have a pronounced activity against other RNA and DNA containing viruses, including human immunodeficiency virus (HIV). 

Daclafab (Daclatasvir) is an inhibitor of the non-structural protein 5A (NS5A), a multifunctional protein required for HCV replication, and thus suppresses two stages of the life cycle of the virus-viral RNA replication and virion assembly.

Based on in vitro data and computer simulation data, it has been shown that Daclatasvir interacts with the N-terminus within domain 1 of the protein, which can cause structural distortions that interfere with the function of the NS5A protein. 

It was found that the preparation is a potent phenotypic inhibitor of the hepatitis C virus replication of the genotypes 1a, 1b, 2a, 3a, 4a, 5a and 6a with effective concentrations (50% reduction, EC50) from picomolar to low nanomolar.

INDICATIONS FOR USE?

Treatment of chronic hepatitis C in patients with compensated liver disease 
(including cirrhosis) in the following combinations of Daclatasvir: 
- with the preparation of Sofosbuvir for patients with the hepatitis virus of genotypes 1, 3, 4, 5; 
- with the drug asunaprevir for patients with the hepatitis virus of genotype 1b; 
- with drugs asunaprevir, peginterferon alfa, and ribavirin - for patients with the 
hepatitis virus of genotype 1.

DOSAGE AND ADMINISTRATION? 

The recommended dose of Daclafab (Daclatasvir) is 60 mg once daily, regardless of food
intake. The drug should be used in combination with other medicines. Therapy is recommended for patients who have not previously received treatment for chronic hepatitis C, and with the previous ineffectiveness of therapy.

STORAGE CONDITIONS?

At a temperature not exceeding 30 ° C. 

Additional Information:

• Delivery Time: 7 to 14 days

Approx. Rs 3,500 / BottleGet Latest Price

DESCRIPTION

Dacikast 60mg (Daclatasvir) is an inhibitor of non-structural protein 5A (NS5A). Each film-coated tablet contains Daclatasvir Dihydrochloride equivalent to Daclatasvir 30 mg or 60mg. Empirical formula for Daclatasvir Dihydrochloride is C40H50N8 O6. 2HCl. Daclatasvir is white to yellow colour solid and freely soluble in water. The tablets include the following inactive ingredients: Anhydrous Lactose, Microcrystalline cellulose, Croscarmellose sodium, Colloidal silicon dioxide, Magnesium stearate, Opadry Orange

Mechanism of Action

Dasikast Tablets Daclatasvir 60mg is an inhibitor of nonstructural protein 5A (NS5A), a multifunctional protein that is an essential component of the HCV replication complex. Daclatasvir inhibits both viral RNA replication and virion assembly.

Pharmacokinetics

The pharmacokinetic properties of Dasikast (Daclatasvir) were evaluated in healthy adult subjects and in patients with chronic HCV. Following multiple oral doses of Daclatasvir 60 mg once daily in combination with peg interferon alfa and ribavirin in treatment naive patients with genotype 1 chronic HCV, the geometric mean (CV%) Daclatasvir Cmax was 1534 (58) ng/ml, AUC0-24h was 14122 (70) ng*h/ml, and Cmin was 232 (83) ng/ml.

INDICATIONS AND USAGE

Dacikast is indicated in combination with Sofosbuvir for the treatment of patient with chronic hepatitis C virus (HCV) genotype 3 infection.

DOSAGE AND ADMINISTRATION

Treatment with Dacikast should be initiated and monitored by a physician experienced in the management of chronic hepatitis C. The recommended dose of Dacikast is 60 mg once daily, to be taken orally with or without meals. Dacikast must be administered in combination with other medicinal products. The Package Inserts of the other medicinal products in the regimen should also be consulted before initiation of therapy with Dacikast. Recommended regimens and treatment duration are provided in Table 1

CONTRAINDICATIONS

Hypersensitivity to the active substance or to any of the Excipients Co-administration with medicinal products that strongly induce cytochrome P450 3A4 (CYP3A4) and P-glycoprotein transporter (P-gp) and thus may lead to lower exposure and loss of efficacy of Daclatasvir. These active substances include but are not limited to phonation, carbamazepine, oxcarbazepine, phenobarbital, rifampicin, rifabutin, rifapentine, systemic dexamethasone, and the herbal product St John’s wort (Hypericum perforatum).

OVERDOSAGE

There is limited experience of accidental overdose of Daclatasvir in clinical trials. In phase 1 clinical trials, healthy subjects who received up to 100 mg once daily for up to 14 days or single doses up to 200 mg had no unexpected adverse reactions. There is no known antidote for overdose of Daclatasvir. Treatment of overdose with Daclatasvir should consist of general supportive measures, including monitoring of vital signs, and observation of the patient’s clinical status. Because Daclatasvir is highly protein bound (99%) and has a molecular weight >500, dialysis is unlikely to significantly reduce plasma concentrations of Daclatasvir

HOW SUPPLIED AND STORAGE

Dacikast 30 mg tablets are available in bottle pack of 28 tablets. Dacikast 60 mg tablets are available in bottle pack of 28 tablets. Store below 25°C.

Additional Information:

• Delivery Time: 1 To 2 Days